EU cross-border healthcare directive should give industry a bigger part in HTA decisions, says EUCOPE
This article was originally published in Scrip
Executive Summary
The European Union cross-border healthcare directive should include a provision to ensure that the pharmaceutical industry has greater involvement in health technology assessment decisions before they are finalised, says Dr Alexander Natz, secretary general of EUCOPE, the European Confederation of Pharmaceutical Entrepreneurs.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.